[163] In March 2023, a Novo Nordisk official said, based on a randomized, double-blind study (NCT03548935 [164] ) funded by the company, that people using semaglutide to lose weight regained two-thirds of their original weight loss one year (52 weeks) after discontinuing use of the drug
Clinical trials have demonstrated remarkable results with both medications
A case series published in the American Journal of Health-System Pharmacy documented allodynia specifically associated with semaglutide, and a Cureus publication detailed dysesthesia and allodynia with both semaglutide and tirzepatide
The effects of inflammatory cytokines on lymphatic endothelial barrier function
Cardiovascular outcomes included composite endpoints as asserted in the Methods section and Figure 3 ascertains the reduction in those events, individual trials aligned with the cardioprotective benefits of SGLT inhibitor therapy
Tirzepatide : A dual-agonist (GLP-1 + GIP) that targets both hunger and how your body breaks down sugar and fat
